Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
I know, that buy dildos online is cheaper.
Popular Articles

New Survey Shows That Welsh Patients Are Happy With Their GPs
The results of the first Welsh GP patient survey have been published recently.
drugs without prescription
Largest Ever Study Of Suicide In The Military
Four of the nation"s leading experts in suicide research, including Dr. John Mann of Columbia University Medical Center, will carry out the largest study of suicide and mental health among military personnel ever undertaken, with $50 million in funding from the U.S. Army. The announcement came today from the National Institute of Mental Health (NIMH), which signed a memorandum of agreement with the Army in October 2008 authorizing the NIMH to undertake the investigation with Army funding. Study investigators aim to move quickly to identify risk and protective factors for suicide among soldiers and provide a science base for effective and practical interventions to reduce suicide rates and address associated mental health problems.
News of the day
The 45th Annual Meeting Of The American Society Of Clinical Oncology
The following are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2, 2008.
Public Health

Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer

Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women"s Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company"s aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. About OSI Pharmaceuticals OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world"s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche"s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer"s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx"s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx"s Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law. This news release also contains forward-looking statements of OSI. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI"s and its collaborators" abilities to effectively market and sell Tarceva and to expand the approved indications for Tarceva, OSI"s ability to protect its intellectual property rights, safety concerns regarding Tarceva, competition to Tarceva and OSI"s drug candidates from other biotechnology and pharmaceutical companies, the completion of clinical trials, the effects of FDA and other governmental regulation, including pricing controls, OSI"s ability to successfully develop and commercialize drug candidates, and other factors described in OSI Pharmaceuticals" filings with the Securities and Exchange Commission References (1) El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750 (2) Available at American Society of Clinical Oncology: http://www.asco.org/patient/Cancer+Types/Liver+Cancer. (3) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004. (4) Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Bayer HealthCare Pharmaceuticals Inc

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009